NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI

NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differently from traditional antiviral treatments by mimicking a natural cellular feature, making it difficult for viruses to escape. He highlighted successful preclinical and early clinical results, noting the drug's effectiveness against viruses like RSV, influenza, and more recently, monkeypox (MPOX). Proactive: Re ...